Table 2.

Reported allergic reactions to biotechnological substances (Pulmonology)

Biologics	ROA	Feature	Authors	Year	HSR %	IR %	ISR %	Urticaria %	Anaphylaxis %
Benralizumab	s.c.	Humanized	Castro et al. [4]	2014	–	–	16.0	–	0
			FDA [5]	2017	3.0		2.2	–	–
			Park et al. [6]	2019	–		0	0–2.0	–
			Pelaia et al. [7]	2019	0		–	–	0
			Liu et al. [8]	2019	–		2.6	–	–
Lebrikizumab	s.c.	Humanized	Hanania et al. [9]	2015	0–0.9	–	11.1–20.5	–	–
			Hanania et al. [10]	2016	–		6.0–10.0	–	<1.0
			Korenblat et al. [11]	2018	–		2.9	–	1.0
			Simpson et al. [12]	2018	–		1.3	–	0
Mepolizumab	i.v. s.c.	Humanized	Pavord et al. [13]	2012	0–1.0	5–12	–	–	0
			FDA [14]	2015	–	–	3.0–8.0	–	0
			Lugogo et al. [15]	2016	<1	<1.0	3.0	–	0
			Khatri et al. [16]	2019	2.0	–	12.0	–	0
Reslizumab	i.v.	Humanized	Castro et al. [17]	2015	–	–	2.0	–	<1
			FDA [18]	2016	–	–		–	<1
			Murphy et al. [19]	2017	<1	<1		<1	0
Omalizumab	s.c.	Humanized	Cox et al. [21]	2007	<0.2	–	–	–	0.09
			Di Bona et al. [22]	2017	–		3.4	1.0	0
			FDA [24]	2019	–		12.0–45.0	0.2	0.1

ROA route of administration, HSR hypersensitivity reaction, IR infusion reaction, ISR Injection-site reaction